Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Sees Malaria Venture Pact As Template For Branching Out Assets Into New Areas

This article was originally published in PharmAsia News

Executive Summary

In what it calls a template for future agreements that might further leverage its library of compounds, AstraZeneca has agreed to give Medicines for Malaria Venture a no-charge look at about 500,000 proprietary compounds to see if they have potential in Plasmodium falciparum malaria

You may also be interested in...

Growing Malaria Resistance In Southeast Asia Sparks Public-Private Groups To Seek Answers

HONG KONG - The emergence across Southeast Asia of strains of malaria that display increasing tolerance to the more commonly used therapies could undo years of progress in battling the disease, and public-private partnerships are trying to respond as quickly as possible

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts